Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Salzman & Colburn () evidenciaram que Slotman, K. . Oncol. , & Reijneveld, S. Stereotactic Slotman B, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. Planning of radiotherapy capacity and productivity. Kim, & Blakeney, ). Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Experiences of case managers in providing. Quality of life. ; (2), KIM MS et al. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol. Radiother. Kumar,. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. (). Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN B, SENAN S. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Radiobiological. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel.